Skip to main content
. 2017 Jan 2;8(5):7357–7369. doi: 10.18632/oncotarget.14458

Figure 2. The absent of ascorbic acid, increased ROS and abnormal development of femurs in the Akr1A1 KO mice were prevented by ascorbic acid supplement.

Figure 2

A. The ascorbic acid concentration in the blood serum of Akr1A1eGFP/eGFP (n = 6), Akr1A1eGFP/eGFP with ascorbic acid supplement (350 mg/L) (n = 7), Akr1A1eGFP/+ (n = 6) and WT (n = 6) mice. B. and C. The ascorbic acid concentration of blood serum in Akr1A1eGFP/eGFP mice at different time points after the mice were fed with ascorbic acid (350 mg/L) in drinking water (n = 6). D. The ROS concentration in the serum of Akr1A1eGFP/eGFP (n = 6), Akr1A1eGFP/eGFP with ascorbic acid supplement (350 mg/L) (n = 7) and WT (n = 6) mice. The values are represented as the mean ± SE; data were analyzed by the one-way ANOVA with Duncan's new multiple range test. The bars with different letters represent P < 0.05. E. The X-ray images and coronal sections of micro-CT analysis from the femurs of Akr1A1eGFP/eGFP, Akr1A1eGFP/eGFP with ascorbic acid supplement (350 mg/L), Akr1A1eGFP/+ and WT mice.